Occupational Exposure to Carbon Nanotubes and Nanofibers

More documents

Recommendations

Info

Table 3–7. Findings from published MWCNT short-term inhalation toxicology studiesStudy design and exposure/doseObserved pulmonary effectsAuthor/yearSpeciesExposurerouteExposureor dose Granuloma Inflammation FibrosisLi et al. [2007] Mice Inhalation Est. lungdepositiondose: 0.07, 0.14,.21 mg. (eval: atdays 8, 16, and24)NR – NRMitchell et al.[2007]Mice Inhalation 0.3, 1,5 mg/m 36 hr/day for 7 or14 days. (eval: atdays 7 and 14)– – –Arkema[2008]RatsHead-noseinhalation0.1, 0.5,2.5 mg/m 36 hr/day for 5days. (eval: atdays 7 and 28)– (0.1 mg/m 3 )+ (0.5, 2.5mg/m 3 )– (0.1 mg/m 3 )–+ (0.5, 2.5 mg/m 3)Ryman-Rasmussenet al. [2009a]Mice w/preexistingallergicinflammationNose-onlyinhalation100 mg/m 3 for6 hr (~10 mg/kgalveolar dose).(eval: at days 1and 14)Lung injury + + whenpreexistingallergicinflammationexistsMa-Hocket al. [2009]RatsHead-noseinhalation0.1, 0.5,2.5 mg/m 3 6 hr/day–5 days/wk.for 13 weeks.(eval: at week 13)+ + –Porter et al.[2009]MiceWholebodyinhalation10 mg/m 35 hr/day for 2, 4,and 8 days, thenevaluated+ + +Sriram et al.[2009]MiceWholebodyinhalation10 mg/m 35 hr/day for2, 4, and 8 days,then evaluatedNRNeuroinflammationNRSee footnotes at end of table.(Continued)28 NIOSH CIB 65 • Carbon Nanotubes and Nanofibers
Table 3–7 (Continued). Findings from published MWCNT short-term inhalation toxicology studiesStudy design and exposure/doseObserved pulmonary effectsAuthor/yearSpeciesExposurerouteExposureor dose Granuloma Inflammation FibrosisEllinger-Ziegelbauer[2009]RatsNose-onlyinhalation11 and 241mg/m 3 for 6 hr(eval: at days 7,28, and 90)NR + – (11 mg/m 3 )+ (241 mg/m 3 )Ryman-Rasmussen etal. [2009b]MiceNose-onlyinhalation1 or 30 mg/m 3 for 6 hr(~0.2 mg/kg and4 mg/kg alveolardose), (eval: at1 day, and 2, 6,and 14)– – (1 mg/m 3 )+ (30 mg/m 3 )– (1 mg/m 3 )+ (30 mg/m 3 )Pauluhn[2010a]RatsNose-onlyinhalation0.1, 0.4, 1.5 and6 mg/m 3 for 6 hr,5 days/week for13 weeks+(6 mg/m 3 ) – (0.1 mg/m 3 )+ (0.4,1.5,6 mg/m 3 )– (0.1 mg/m 3 )(0.4 mg/m 3 ,focal septalthickening)+(1.5, 6 mg/m 3 )NR = not reported+ = effect observed– = no effect observedNIOSH CIB 65 • Carbon Nanotubes and Nanofibers29
Page 1 and 2:
CURRENT INTELLIGENCE BULLETIN 65Occ
Page 3 and 4: Current Intelligence Bulletin 65Occ
Page 5 and 6: ForewordThe Occupational Safety and
Page 7 and 8: Executive SummaryOverviewCarbon nan
Page 9 and 10: 2009; Pauluhn 2010a; Porter et al.
Page 11 and 12: neurogenic sig nals from sensory ir
Page 13 and 14: possible. Until the results from an
Page 15 and 16: ••Follow exposure and hazard as
Page 17 and 18: Periodic Evaluations••Evaluatio
Page 19 and 20: ContentsForeword ..................
Page 21 and 22: A.3.2 Comparison of Short-term and
Page 23 and 24: ESPFeFMPSFPSSgGMGSDHCLHECHEPAhrISOI
Page 25 and 26: AcknowledgementsThis Current Intell
Page 27 and 28: 1 IntroductionMany nanomaterial-bas
Page 29: 2 Potential for ExposureThe novel a
Page 32 and 33: CNMs, with MWCNT agglomerates obser
Page 34 and 35: composite materials with local exha
Page 36 and 37: information on air contaminants. Sa
Page 39 and 40: 3 Evidence for Potential Adverse He
Page 41 and 42: decreasing agglomerate size increas
Page 43 and 44: examined up to 60 days post-exposur
Page 45 and 46: 3.3 SWCNT and MWCNTIntraperitoneal
Page 47 and 48: The same potency sequence was obser
Page 49 and 50: Table 3-3. Findings from published
Page 51 and 52: Table 3-5. Findings from published
Page 53: Table 3-6. Findings from published
Page 57: Table 3-8. Findings from published
Page 60 and 61: length, respectively) [Muller et al
Page 63 and 64: 5 CNT Risk Assessment and Recommend
Page 65 and 66: A-6). Risk estimates derived from o
Page 67 and 68: Table 5-4. Factors, assumptions, an
Page 69 and 70: and analytical methods. NIOSH is re
Page 71 and 72: Table 5-5. Recommended occupational
Page 73 and 74: deficits in animals or clinically s
Page 75: (3) Rat lung dose estimationIn the
Page 78 and 79: tasks where worker exposures exceed
Page 80 and 81: As part of the evaluation of worker
Page 82 and 83: Table 6-1. EC LODs and LOQs for 25-
Page 84 and 85: 6.2 Engineering ControlsOne of the
Page 86 and 87: Table 6-6 (Continued). Examples of
Page 88 and 89: Table 6-7 (Continued). Engineering
Page 90 and 91: exposure estimates for SWCNT on ind
Page 92 and 93: Table 6-8. Respiratory protection f
Page 94 and 95: ••Workers in areas or in jobs w
Page 97 and 98: 7 Research NeedsAdditional data and
Page 99 and 100: ReferencesACGIH [1984]. Particle si
Page 101 and 102: Bolton RE, Vincent HJ, Jones AD, Ad
Page 103 and 104: eport issued on July 22, 2011. NEDO
Page 105 and 106:
Kobayashi N, Naya M, Mizuno K, Yama
Page 107 and 108:
Methner M, Hodson L, Geraci C [2010
Page 109 and 110:
Human Services, Centers for Disease
Page 111 and 112:
Piegorsch WW, Bailer AF [2005]. Qua
Page 113 and 114:
AD, Baron PA [2003]. Exposure to ca
Page 115:
Varga C, Szendi K [2010]. Carbon na
Page 119 and 120:
ContentsA.1 Introduction ..........
Page 121 and 122:
A.1 IntroductionThe increasing prod
Page 123 and 124:
provide an informal check on the es
Page 125 and 126:
these same dose groups; this effect
Page 127 and 128:
Table A-1. Rodent study information
Page 129 and 130:
the deposited (no clearance) and th
Page 131 and 132:
The other BMDS models failed to con
Page 133 and 134:
Figure A-2. Benchmark dose model (m
Page 135 and 136:
Figure A-3 (continued). Benchmark d
Page 137 and 138:
Table A-3. Benchmark dose estimates
Page 139 and 140:
Table A-5. Benchmark dose estimates
Page 141 and 142:
histopathology grade 2 or higher lu
Page 143 and 144:
Table A-8. Working lifetime percent
Page 145 and 146:
developing early-stage adverse lung
Page 147 and 148:
Figure A-4. Dose-response relations
Page 149 and 150:
cell surface area). However, the wo
Page 151 and 152:
purified or unpurified (with differ
Page 153 and 154:
Table A-9. Comparison of rat or hum
Page 155 and 156:
A.6.1.3 Pulmonary Ventilation RateT
Page 157 and 158:
used as the effect levels in evalua
Page 159 and 160:
the DF estimate, although a larger
Page 161 and 162:
or overloading, of particle clearan
Page 163 and 164:
Table A-13. Human-equivalent retain
Page 165 and 166:
A.7.1 Particle CharacteristicsBoth
Page 167 and 168:
and density. The following MMAD and
Page 169:
Table A-15. CNT lung dose normalize
Page 172 and 173:
B.1 Key Terms Related toMedical Sur
Page 175 and 176:
APPENDIX CNIOSH Method 5040
Page 177 and 178:
filter. In the method evaluation, d
Page 179 and 180:
Most of the studies on sampling art
Page 181 and 182:
e analyzed to determine the onset o
Page 184:
Delivering on the Nation’s promis
show all

Occupational Exposure to Carbon Nanotubes and Nanofibers

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?